Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc)- Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Stud ...
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.2552
https://www.valueinhealthjournal.com/article/S1098-3015(17)32886-3/fulltext
Title :
Adding Ramucirumab To Second-Line Irinotecan, 5-Fluorouracil and Folinic Acid (Folfiri) Treatment for Metastatic Colorectal Carcinoma (Mcrc)- Resource Utilization Data from Raise, A Global, Randomized, Double-Blind, Multicenter Phase 3 Stud ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32886-3&doi=10.1016/j.jval.2017.08.2552
First page :
A871
Section Title :
SELECTED HEALTH CARE TREATMENT STUDIES -MEDICAL DEVICE/DIAGNOSTICS
Open access? :
No
Section Order :
2356